| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Groupe d'étude sur la maladie de Hodgkin, Institut de Recherches sur les Leucémies et les Maladies du Sang, Hôpital Saint-Louis, Paris 10°, France
The current Rye classifcation no longer appears fully satisfactory for staging of Hodgkin's disease. As a result of a study of clinical, radiological, and biological data taken from the records of 402 patients from 1966 to 1970, we suggest that a new classification should take into account the following factors: the site of onset of the disease which enables a distinction between teh high cervical, mediastinal, retroperitoneal, and axillary forms, which all have their specific lymphatic extent; the involvement if any of the spleen; the biological signs as well as clinical symptoms for identification of the systemic syndrome. These changes could bring about significant consequences for therapy, especially in reducing irradiation volumes and in advocating the use of chemotherapy combined with radiotherapy.
This article has been cited by other articles:
![]() |
J. Landman-Parker, H. Pacquement, T. Leblanc, J. L. Habrand, M. J. Terrier-Lacombe, Y. Bertrand, Y. Perel, A. Robert, C. Coze, I. Thuret, et al. Localized Childhood Hodgkin’s Disease: Response-Adapted Chemotherapy With Etoposide, Bleomycin, Vinblastine, and Prednisone Before Low-Dose Radiation Therapy--Results of the French Society of Pediatric Oncology Study MDH90 J. Clin. Oncol., April 7, 2000; 18(7): 1500 - 1507. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |